Market Overview

Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences


Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that Jay R. Luly, Ph.D., President and Chief Executive Officer, will
present at the following investor conferences:

September 6, 9:40 am ET; Baird 2018 Global Healthcare Conference, New

September 13, 8:00 am ET; Morgan Stanley 16th Annual Global
Healthcare Conference, New York

A live webcast of each presentation will be accessible by visiting the
"Events and Presentations" section on the "Investors" page of Enanta's
website at
A replay of the webcasts will be available following the presentation
and will be archived for approximately 30 days.

About Enanta
Enanta Pharmaceuticals is using its robust,
chemistry-driven approach and drug discovery capabilities to become a
leader in the discovery and development of small molecule drugs for the
treatment of viral infections and liver diseases. Two protease
inhibitors, glecaprevir and paritaprevir, discovered and developed
through Enanta's collaboration with AbbVie, have now been approved
around the world as part of AbbVie's regimens for the treatment of
hepatitis C virus (HCV) infection, sold under the tradenames MAVYRET™
(U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir) and VIEKIRAX®
(paritaprevir/ritonavir/ombitasvir) (ex-U.S.).

Royalties from the AbbVie collaboration are helping to fund Enanta's
research and development efforts, which are currently focused on the
following disease targets: non-alcoholic steatohepatitis (NASH), primary
biliary cholangitis (PBC), respiratory syncytial virus (RSV) and
hepatitis B virus (HBV). Please visit
for more information.

View Comments and Join the Discussion!